

Status of Serum Vitamin B12 in Type 2 Diabetes Mellitus Patients under Metformin Therapy

Sanjay Kumar Sah,¹ Suprita Gupta,¹ Amit Chandra Jha,¹ Surendra Marasini,¹ Tapeshwar Yadav,² Brijesh Shrestha³

¹Department of Biochemistry, National Medical College, Birgunj, Nepal; ²Department of Biochemistry, Madan Bhandari Academy of Health Sciences, Hetauda, Nepal; ³Department of Pathology, National Medical College, Birgunj, Nepal.

ABSTRACT

Introduction: Type 2 diabetes mellitus, a prevalent global health problem, is a major cause of morbidity and mortality. Metformin, the most widely used hypoglycemic agent can lead to a deficiency of vitamin B_{12} . Very less information is available regarding the relationship between metformin therapy and vitamin B12 deficiency in the Nepalese population.

Objectives: The study aims to evaluate the level of vitamin B_{12} in cases of diabetes mellitus under metformin therapy and to access the relationship of serum vitamin B_{12} level with the duration of metformin therapy.

Methods: A hospital-based cross-sectional study with 300 diagnosed diabetes mellitus cases under metformin therapy were enrolled in the study after the consent was taken. The prior ethical clearance was taken and the duration of the study was from December 2021 to June 2022.

Results: The study showed 78% (n=234) of the total diabetic cases under metformin therapy had lower vitamin B_{12} . In 50-60 years, age group, 91% of them were vitamin B_{12} deficient. Vitamin B_{12} deficient cases were more with the increase in duration and dose of metformin therapy. All the diabetics who were under medication for 16-20 years had lower vitamin levels. About 94% (n=200) of the diabetics taking more than 1000 mg/day were vitamin B_{12} deficient whereas only 39% (n=34) of diabetics taking less than 1000mg/day were found to be deficient.

Conclusions: Vitamin B12 is deficient in diabetics under long-term and higher doses of metformin therapy. Diabetic patients who are undergoing metformin treatment should monitor their vitamin B12 status as they are more prone to vitamin B12 deficiency.

Keywords: Diabetes mellitus; metformin; vitamin B_{12} .

INTRODUCTION

Type 2 Diabetes Mellitus (T2DM), one of the commonest endocrine disorders, is a prevalent global health problem and is on a constant rise.¹ This stands to be a major cause of morbidity and mortality for millions of populations worldwide.²

Correspondence

Citation

Dr. Sanjay Kumar Sah Email: drsanjay@nmcbir.edu.np Orcid id: 0000-0001-9242-684X



Sah SK, Gupta S, Jha AC, Marasini S, Yadav T, Shrestha B. Status of Serum Vitamin B12 in Type 2 Diabetes Mellitus Patients under Metformin Therapy. Nepal J Health Sci. 2022 Jul-Dec; 2(2):9-14. Metformin, the most widely used hypoglycemic agent is considered the first-line drug in DM due to various reasons such as cost-effectiveness, beneficial effect on weight, high potency, least side effects, long-standing evidence of safety, etc. A documented data of approximately 120 million diabetic patients is under metformin treatment worldwide.³

The deficiency of vitamin B₁₂ in T2DM is induced by prolonged metformin therapy and is a least known and understood side effect. It is often a scenario with prolonged use, higher doses taken, and with the elderly.⁴ Despite a high prevalence of T2DM in Nepal, restricted information regarding its side effects is available to date. This study aims to assess the status of vitamin B₁₂ levels in diabetics under metformin therapy. The findings of the study will be beneficial to understand the pattern of vitamin B₁₂ deficiency in T2DM patients and probably help in the better therapeutic management of T2DM.

METHODS

This is a hospital-based observational crosssectional study carried out at National Medical College, Birgunj, Nepal for six months duration from 17th December 2021 to 16th June 2022. The study population consisted of 300 diagnosed cases of diabetic mellitus (type 2), visiting the outpatient departments of internal medicine or wards. All the cases were confirmed diabetics as per ADA criteria and already receiving metformin treatment for DM. A nonprobability purposive sampling technique was used to enroll the subjects for the study. Ethical clearance (Ref. F-NMC/574/078-079) was taken from the Institutional Review Committee (IRC), National Medical College, Birgunj, Nepal. The proper informed consent was taken by the subjects enrolled in this study.

Diagnosed cases of DM under metformin therapy in the age group of 30 to 60 years, those willing to participate in the study were the inclusion criteria. All the participants were Nepalese citizens. The exclusion criteria for this study were those with chronic renal failure, diagnosed cases of benign and malignant tumors, ages below 30 years and above 60 years, and those not willing to participate in the study. The samples collected were analyzed using Beckman Access2, California, and a normal range of Vitamin B12 was taken as per the standard guideline and reference given by the producing company.

All the data were entered in Microsoft Excel 2010 and converted to SPSS version 22 accordingly. The Chi square test was applied to compare the categorical variables. The numerical data were expressed in the mean and standard deviation. Independent t-test was used to compare the mean and the standard deviation between low and normal vitamin B_{12} groups. Pearson correlation was used to find out the correlation between the serum vitamin B_{12} statuses with other variables. The P value of less than 0.05 was considered statistically significant.

RESULTS

The finding of this study showed that 78% (n=234) of the study participants who were diagnosed cases of diabetes mellitus (type 2) and under metformin therapy, were deficient in serum vitamin B12. The remaining 22% of diabetics under metformin therapy, however, had normal serum vitamin B₁₂. The maximum number of participants in this study, about 44% were in the 50-60 years age group, followed by 30% from the 41-50 years age group and about 23% from less than 40 years of age group. Among participants in the 50-60 years age group, 91.6% of them were vitamin B₁₂ deficient as shown in Table 1.

Vitamin B_{12} deficient cases were more with the increase in duration and dose of metformin therapy. All the diabetics (100%), who were under metformin therapy for 16-20 years had lower vitamin B_{12} levels. About 94% (n=200) of the diabetics taking more than 1000 mg/day were vitamin B_{12} deficient whereas only 39% (n=34) of diabetics taking less than 1000mg/day were found to be deficient.

S. No.	Age group (years)	Total Participants	Low Vitamin B ₁₂ n (%)	Normal Vitamin B12 n (%)	p-value*	
1	<40	79	40 (50.6%)	39(49.4%)		
2	41-50	90	74 (82.2%)	16(17.8%)	0.00	
3	50-60	131	120 (91.6%)	11(8.4%)	0.00	

Table 1: Distribution of vitamin B₁₂ status in different age groups.

S. No	Gender	Total Participants	Low Vitamin B ₁₂ n (%)	Normal Vitamin B12 n (%)	p-value*	
1	Female	156	124 (79.5%)	32(20.5%)		
2	Male	144	110 (76.4%)	34(23.6%)	0.00	

Table 2: Distribution of vitamin B₁₂ status based on gender.

	Table 3: Medication years and vitamin B ₁₂ status.						
0.	Medication Years	Low Vitamin B ₁₂ n (%)	Normal Vitamin B ₁₂ n (%)	P value*			
	<5	38(43.7%)	49(56.3%)				
	6-10	142(89.9%)	16(10.1%)	0.00			
				0.00			

45(97.8%)

9(100%)

In this study, 52% (n=156) of the total participants who were diagnosed cases of diabetes mellitus (type 2) and under metformin therapy were female, compared to 48% male (n=144).

11-15

16-20

S.N

1. 2.

3.

4.

Among the diabetics under metformin therapy for 6-10 years (about 53% of the total participants), 89.9% (n=142) were found to be deficient in vitamin B₁₂. However, the percentage of vitamin B₁₂ deficient participants increased with a longer duration of metformin therapy, i.e., 97.8% in 11-15 years of metformin therapy and 100% in 16-20 years of metformin therapy as shown in Table 3.

Lower serum vitamin B_{12} was seen with the participants taking higher doses of metformin per day as shown in Table 4.

1(2.2%)

0(0%)

The correlation analysis revealed the correlation of serum vitamin B12 status with other variables. Significant negative correlations were seen with age (-0.48, 0.00), duration of diabetes mellitus diagnosed (-0.52, 0.00), medication years (-0.52, 0.01), doses of metformin (-0.71, 0.01), fasting blood glucose (-0.33, 0.01), postprandial blood glucose (-0.26, 0.01), HbA1C (-0.19, 0.01) and MCV (-0.34, 0.01), as depicted in table 6.

Table 4. Dose of metorinin per day and vitanin D12 status.						
S. No.	Dose of metformin/day	Low Vitamin B ₁₂ n (%)	Normal Vitamin B12 n (%)	P value*		
1.	<1000	34(39.1%)	53(60.9%)	0.00		
2.	1100-2000	200(93.9%)	13(6.1%)	0.00		

Table 4: Dose of metformin per day and vitamin B₁₂ status.

Table 5: Comparison	of variables betwee	n low and norn	1al vitamin H	312 status

S. No.	Variables	Vitamin B ₁₂	Mean ± SD	P value*	
1	$G_{\mu\alpha\alpha\alpha\alpha} = (m\alpha/dI)$	Low	109.93 ± 16.82	0.00	
1.	Glucose F (llig/dL)	Normal	99.44 ± 13.84		
2	$C_{\rm business}$ DD (m g/dL)	Low	166.77 ± 35.48	0.00	
۷.	Glucose PP (mg/dL)	Normal	149.26 ± 20.85		
3.	$IIb \wedge 1_{\circ} (0/)$	Low	$6.34{\pm}~1.09$	0.04	
	HDA1C (%)	Normal	6.05 ± 0.7		
4.	Vitamin B ₁₂ (pg/mL)	Low	146.19 ± 28.49	0.01	
		Normal	310.94 ± 107.27	0.01	
5.		Low	11.28 ± 1.64	0.01	
	HD (gm%)	Normal	13.04 ± 1.30	0.01	
6.		Low	94.37 ± 9.19	0.01	
	MC V (IL)	Normal	87.58 ± 6.61	0.01	

S. No.	Variables	r value	P value*
1	Age	-0.48	0.00*
2	Gender	0.06	0.2
3	Smoking	0.03	0.5
4	Alcohol	-0.01	0.8
5	Years of Diagnosis of DM	-0.52	0.00*
6	Medication Duration (years)	-0.52	0.01*
7	Dose of Metformin	-0.71	0.01*
8	Glucose fasting	-0.33	0.01*
9	Glucose PP	-0.26	0.01*
10	HbA1c	-0.19	0.01*
11	Vitamin B12	1	-
12	Hemoglobin	0.51	0.01*
13	MCV	-0.34	0.01*

Table 6: Correlation of serum vitamin B₁₂ status with variables.

DISCUSSION

This is a hospital-based observational cross-sectional study comprising 300 participants who were diagnosed cases of diabetes mellitus (type 2) under metformin therapy was carried out for 6 months. The finding of this study showed that 78% (n=234) of the study participants who were diagnosed with cases of diabetes mellitus (type 2) and under metformin therapy, were deficient in serum vitamin B₁₂. The remaining 22% of diabetics under metformin therapy, however, had normal serum vitamin B₁₂. The maximum number of participants in this study, about 44% were in the 50-60 years age group, followed by 30% from the 41-50 years age group and about 23% from less than 40 years of age group. Among the 50-60 years age group, 91.6 % of them were vitamin B12 deficient. vitamin B12 deficient cases were more with the increase in duration and dose of metformin therapy. All the diabetics (100%), who were under metformin therapy for 16-20 years had lower vitamin B12 levels. About 94% (n=200) of the diabetics taking more than 1000 mg/day were vitamin B₁₂ deficient whereas only 39% (n=34) of diabetics taking less than 1000mg/day were found to be deficient.

Vitamin B_{12} , a water-soluble vitamin is required for hematopoiesis, the functioning of the central nervous

system as well as the peripheral nervous system, and in DNA synthesis of all cells. The common and frequent adverse effects related to metformin are not severe and usually lead to temporary and self-restricting gastrointestinal (GI) disturbance.5 Apart from GI this issues, other clinically important adverse effects that have been reported include vitamin B12 malabsorption. A study that was done in 2016 in the Brazilian population receiving extended metformin therapy concluded that the frequency of vitamin B₁₂ deficiency ranges from 5.8% to 30%.6 The reported vitamin B₁₂ deficiency in the general Indian population varies from 12% to 67% which is very much high as compared to that in the western population with only 5-7%.7,8 The results of this study showed similar findings to the study done in 2012, that showed patients under metformin therapy had statistically significant lower serum vitamin B₁₂ levels compared to those not receiving metformin (P < .0001; 95 % confidence interval [CI] = -220 to -84 pg/mL).4

It is postulated that a predominantly vegetarian diet or strict vegans could be one of the causes of the higher prevalence of vitamin B₁₂ deficiency in India.⁷ This can also apply to the Nepalese population as well. A deficiency of serum vitamin B₁₂ in our body causes megaloblastic anemia, neuropathy, memory, and cognitive impairment. Neuropathy, one of the established common complications in DM is similar to the clinical features of serum vitamin B_{12} deficient neuropathy (indistinguishable by nerve conduction studies also). There's the probability that vitamin B_{12} deficient neuropathy can be misdiagnosed as diabetic neuropathy or it may contribute to worsening of diabetic neuropathy in the long run of disease course.⁴

Serum vitamin B₁₂ deficiency in the individual induced by metformin has been ascribed to the binding of the hydrophobic tail of biguanide to the hydrocarbon core of membranes. The biguanide group that is found to be positively charged (protonated) gives a positive charge to the membrane and can displace divalent cations such as calcium. The study done in 2006 showed that after adjusting for confounders, the clinically important and statistically significant association of serum vitamin B12 deficiency with both dose and duration of metformin therapy, which is similar to the findings of this study. The study states that each 1-gram/day metformin dose increment conferred an odds ratio of 2.88 (95% confidence interval, 2.15-3.87) that is developing vitamin B_{12} deficiency (p < .001). For the participants who used metformin for 3 years or more, the adjusted odds ratio was found to be 2.39 (95% confidence interval, 1.46-3.91) (p = .001) compared with those participants receiving metformin tablets for less than 3 years.⁹ The uptakes of vitamin B₁₂ from the diet into the ileal cells are calcium-dependent and so metformin intake can interfere with the uptake of vitamin B₁₂.¹⁰

The first case of serum vitamin B_{12} deficiencyinduced megaloblastic anemia due to long-term (8 years) metformin therapy was reported in 1980.¹¹ A study in India done in 2017, reported similar results of this study that metformin intake for diabetes was associated with a low level of serum vitamin B_{12} when adjusted for duration of diabetes. The increase in the duration of diabetes was associated with a higher number of deficient serum vitamin B_{12} levels. The serum vitamin B_{12} levels were 267.7 ± 194.4 pmol/L in the metformin group and 275.1 \pm 197.2 pmol/L in the no metformin group (p = 0.78). But when adjusted for duration of diabetes, metformin use was associated with 87.7 \pm 37.7 pmol/L (95% confidence interval [CI], -162.1--3.3, p = 0.02) i.e., lower serum Vitamin B12 levels.¹¹

As per the review of literature, it has been stated in a study that reduced absorption of vitamin B12 manifested as decreased serum vitamin B12 levels, occurred as early as 3-4 months after the initiation of metformin treatment. It also states that, with the increase in duration i.e.; 5-10 years after metformin therapy, symptomatic deficiency of vitamin B12 occurred. This finding can be justified by the fact that the body can store of vitamin B12 is huge amount i.e., 2500 µg, in comparison to per day loss/requirement $(1-2 \mu g)$, and depletion of the pre-existing body store vitamin B12 thus takes 3-15 years.¹² It has been mentioned that biochemical deficiency is considered when serum vitamin B₁₂ levels are between 200pg/ ml - 300pg/ml and symptoms suggestive of vitamin B_{12} deficiency occur when levels go below 200pg/ml. Vitamin B₁₂ supplements can reverse hematological manifestations within days to weeks. Reversal of neurological damage is still doubtful.¹²

A study done in 2021 in Nepal, showed similar results of this study. The mean serum vitamin B12 level is estimated as low as the duration of metformin treatment increases. The gender, and age relation with the development of vitamin B12 deficiency was not significant. Out of 210 patients, 107 patients were having severe vitamin B12 deficiency and 63 patients had a borderline vitamin B12 deficiency level which shows that the deficiency increases per longer use of metformin therapy, which shows a prevalence of 50.95%.13 Similarly, a study in India during 2019 showed, 164 of 408 cases (on metformin therapy for >3 months) had low vitamin B₁₂ as against 22 out of 242 controls (never on metformin therapy). But, average serum vitamin B12 was low in cases with less duration of DM when compared to cases with longer duration.14

The smaller sample size is the limitation of this study. The study could not incorporate the confounding factors that may also lead to lower vitamin B_{12} levels. The study also did not compare serum vitamin B12 levels with the matched non-diabetic population.

CONCLUSION

Vitamin B_{12} is deficient in diabetics under longterm and higher doses of metformin therapy. The dose of metformin taken has a significant effect on lowering the level of vitamin B_{12} . Similarly, the duration of metformin therapy in diabetes mellitus is also significantly related to vitamin B_{12} deficiency. The results can be undertaken by medical professionals and evaluation of serum vitamin B12 of the diabetic patients on metformin therapy should be regularly monitored. It is also recommended that the pre-evaluation of serum vitamin B12 will be of great concern before starting metformin therapy in newly diagnosed cases of diabetes mellitus. It can also be advised that prophylactically vitamin B12 supplementation can be instituted in diabetic patients on metformin therapy.

Conflict of Interest: None

NJHS

REFERENCES

- Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, Malanda B: IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271-81. [DOI]
- Agarwal P, Mital P, Meena VK, Mital P, Nawal CL, Goyal KL. A comparative study of levels of vitamin B12 in patients of type 2 diabetes mellitus on metformin and not on metformin at tertiary care center. Int J Adv Med.2016;3(3):759-763. [DOI]
- DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin dependent diabetes mellitus- The Multicenter Metformin Study Group. N Engl J Med.1995;333(9):541-9. [DOI]
- Kos E, Liszek M, Emanuele M, Durazo-Arvizu R, Camacho P. Effect of metformin therapy onvitamin D and vitamin B₁₂ levels in patients with type 2 diabetes mellitus. EndocrPract.2012;18(2):179-184. [DOI]
- 5. Strack T: Metformin: a review. Drugs Today (Barc). 2008;44:303-14. [DOI]
- Damião CP, Rodrigues AO, Pinheiro MF, Cruz RA Filho, Cardoso GP, TaboadaGF, Lima GA: Prevalence of vitamin B12 deficiency in type 2 diabetic patients using metformin: a cross-sectional study. Sao Paulo Med J. 2016;134:473-9. [DOI]
- Yajnik C, Deshpande SS, Lubree HG, Naik SS, Bhat DS, Uradey BS, et al. Vitamin B12 deficiency and hyperhomocysteinemia in rural and urban Indians. J Assoc Physicians India. 2006;54:775-782. [PubMed]
- Kapil U, Bhadoria AS. Prevalence of folate, ferritin and cobalamin deficiencies amongst adolescent in India. J Family Med Prim Care. 2014;3(3):247-249.
 [DOI]
- Ting RZ, Szeto CC, Chan MH, Ma KK, Chow KM. Risk factors of vitamin B12 deficiency in patients receiving metformin. Arch Intern Med. 2006;166(18):1975-1979. [DOI]
- 10. Bauman WA, Shaw S, Jayatilleke E, Spungen AM, Herbert V. Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin. Diabetes Care. 2000;23(9):1227-31. [DOI]
- 11. Raizada N, Jyotsna VP, Sreenivas V, Tandon N. Serum Vitamin B12 Levels in Type 2 Diabetes Patients on Metformin Compared to those Never on Metformin-A Cross-sectional Study. Indian J Endocrinol Metab. 2017;21(3):424-428. [DOI]
- 12. Mazokopakis EE, Starakis IK. Recommendations for diagnosis and management of metformin induced vitamin B12 deficiency. Diabetes Res Clin Pract. 2012;97(3):359-367. [DOI]
- 13. Malla D, Bajracharya MR, Karki BB, Rajouria AD, Shrestha PS. Prevalence of Vitamin B12 Deficiency in Patients with Type II Diabetes Mellitus on Metformin. Jour of Diab and Endo Assoc of Nepal 2021;5(1):39-43. [DOI]
- 14. Yashaswini LS. A study on serum vitamin B12 levels in type 2 diabetic women and its correlation with metformin therapy. Int J Med Res Rev. 2019;7(4):332-338. [DOI]